Patients (n) | 57 | 85 |
Age, median (range) | 50 (17–79) | 46 (19–65) |
Female/male, % | 68/32 | 80/20 |
Disease duration at entry, months, median (range) | 7 (2–24) | 8 (2–12) |
Rheumatoid factor found at entry, % | 58 | 67 |
HLA-DR4 present, % | 56 | 64 |
Mallya score at entry, median (range) | 2.7 (1.5–3.7) | 2.5 (1.3–3.6) |
Larsen’s score at entry, median (range) | 0 (0–28) | 2 (0–22) |
Followup period at the latest visit, months, median (range) | 91 (18–111) | 60 (36–84) |
% Treated with SAARDs during the study | 100 | 100 |
Maximum symptomatic time before the start of SAARD treatment, months | 24 | 12 |
Patients with joint replacements during the study | 5 | 5 |